Clearside Biomedical, Inc. (CLSD)
After hours:
| Previous Close | 1.2600 |
| Open | 1.2800 |
| Bid | 1.2700 x 100 |
| Ask | 1.3700 x 100 |
| Day's Range | 1.2400 - 1.3900 |
| 52 Week Range | 0.6500 - 2.1200 |
| Volume | |
| Avg. Volume | 365,524 |
| Market Cap | 98.632M |
| Beta (5Y Monthly) | 2.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5300 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
GlobeNewswireClearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
- Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - Tony Gibney Tony Gibney was appointed to the Board of Directors of Clearside Biomedical. ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointe
GlobeNewswireClearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at
GlobeNewswireClearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Victor Chong, M.D., MBA Victor Chong, M.D., MBA was appointed as Chief Medical Officer for Clearside Biomedical. ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced to
